Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Combination of oxaliplatin, fluorouracil, and leucovorin in the treatment of fluoropyrimidine-pretreated patients with metastatic colorectal cancer
Autore:
Lee, JH; Lee, JH; Kim, TW; Lee, KH; Kang, YK; Lee, JS; Kim, SH; Kim, HC; Yu, CS; Kim, JC; Kim, WK;
Indirizzi:
Univ Ulsan, Coll Med, Asan Med Ctr, Dept Med,Songpa Gu, Seoul 138040, South Korea Univ Ulsan Seoul South Korea 138040 Songpa Gu, Seoul 138040, South Korea Univ Ulsan, Coll Med, Asan Med Ctr, Dept Surg, Seoul 138040, South Korea Univ Ulsan Seoul South Korea 138040 Dept Surg, Seoul 138040, South Korea
Titolo Testata:
JOURNAL OF KOREAN MEDICAL SCIENCE
fascicolo: 1, volume: 16, anno: 2001,
pagine: 69 - 74
SICI:
1011-8934(200102)16:1<69:COOFAL>2.0.ZU;2-I
Fonte:
ISI
Lingua:
ENG
Soggetto:
HIGH-DOSE LEUCOVORIN; FIRST-LINE TREATMENT; PHASE-II; 5-FLUOROURACIL REGIMEN; CHEMOTHERAPY; INFUSION; RESISTANT; CARCINOMA; THERAPY; TRIAL;
Keywords:
colorectal neoplasms; oxaliplatin; fluorouracil; leucovorin;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
31
Recensione:
Indirizzi per estratti:
Indirizzo: Lee, JH Univ Ulsan, Coll Med, Asan Med Ctr, Dept Med,Songpa Gu, 388-1 Poongnap Dong, Seoul 138040, South Korea Univ Ulsan 388-1 Poongnap Dong Seoul South Korea 138040 uth Korea
Citazione:
J.H. Lee et al., "Combination of oxaliplatin, fluorouracil, and leucovorin in the treatment of fluoropyrimidine-pretreated patients with metastatic colorectal cancer", J KOR MED S, 16(1), 2001, pp. 69-74

Abstract

There has been no standard therapy for patients with metastatic colorectalcancer who have failed to first-line fluorouracil-based treatment. The present study was designed to assess the efficacy and toxicities of a combination of oxaliplatin, 5-fluorouracil (5-FU) and leucovorin in fluoropyrimidine-pretreated patients with metastatic colorectal cancer. Chemotherapy consisted of oxaliplatin 85 mg/m(2) on day 1, followed by leucovorin 20 mg/m(2) and 5-FU 1,200 mg/m(2) on days 1 and 2. Treatment courses were repeated every two weeks. Thirty-nine patients were enrolled in this study. All patients previously received fluoropyrimidine-based chemotherapy. Thirty-one patients were assessable for response and 33 for treatment toxicity. Six patients required dose reduction of 5-FU due to grade III/IV cytopenia. Nausea/vomiting and peripheral neuropathy were common non-hematologic toxicities. Overall response rate was 42.0% including 3 complete response and 10 partial response. The median response duration was 91 days (range, 28-224+). The median duration of progression-free survival was 132 days (range, 40-308). A combination of oxaliplatin, 5-FU, and leucovorin showed high response rate in fluoropyrimidine-pretreated patients with metastatic colorectal cancer, but the duration of response was relatively short. It may be worthwhile to explore its therapeutic potential in the first-line treatment setting.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 27/09/20 alle ore 19:18:14